IRulya Therapeutics, Inc. (IRLA)
39.94
-0.65
(-1.60%)
USD |
NASDAQ |
Nov 19, 16:00
39.12
-0.82
(-2.05%)
Pre-Market: 20:00
IRulya Therapeutics Enterprise Value : 79.19M for Nov. 19, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 19, 2026 | 79.19M |
| November 18, 2026 | 79.85M |
| November 17, 2026 | 77.68M |
| November 16, 2026 | 76.57M |
| November 13, 2026 | 79.05M |
| November 12, 2026 | 79.03M |
| November 11, 2026 | 77.56M |
| November 10, 2026 | 77.85M |
| November 09, 2026 | 72.92M |
| November 06, 2026 | 70.10M |
| November 05, 2026 | 68.38M |
| November 04, 2026 | 70.78M |
| November 03, 2026 | 72.30M |
| November 02, 2026 | 72.69M |
| October 30, 2026 | 72.08M |
| October 29, 2026 | 70.73M |
| October 28, 2026 | 72.09M |
| October 27, 2026 | 71.60M |
| October 26, 2026 | 70.49M |
| October 23, 2026 | 72.22M |
| October 22, 2026 | 71.96M |
| October 21, 2026 | 73.84M |
| October 20, 2026 | 79.53M |
| October 19, 2026 | 73.61M |
| October 16, 2026 | 71.15M |
| Date | Value |
|---|---|
| October 15, 2026 | 72.37M |
| October 14, 2026 | 69.08M |
| October 13, 2026 | 66.92M |
| October 12, 2026 | 71.52M |
| October 09, 2026 | 70.84M |
| October 08, 2026 | 68.43M |
| October 07, 2026 | 65.75M |
| October 06, 2026 | 65.84M |
| October 05, 2026 | 67.15M |
| October 02, 2026 | 68.27M |
| October 01, 2026 | 69.77M |
| September 30, 2026 | 70.11M |
| September 29, 2026 | 59.53M |
| September 28, 2026 | 57.33M |
| September 25, 2026 | 59.36M |
| September 24, 2026 | 58.34M |
| September 23, 2026 | 58.50M |
| September 22, 2026 | 59.72M |
| September 21, 2026 | 59.36M |
| September 18, 2026 | 57.81M |
| September 17, 2026 | 55.30M |
| September 16, 2026 | 55.46M |
| September 15, 2026 | 57.17M |
| September 14, 2026 | 56.91M |
| September 11, 2026 | 57.89M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Korsana Biosciences, Inc. | 1.184B |
| PepGen Inc. | 183.00M |
| Q32 Bio, Inc. | -30.98M |
| Bridgebio Oncology Therapeutics, Inc. | -42.25M |
| Oncolytics Biotech, Inc. | 49.62M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -27.74M |
| Total Expenses (Quarterly) | 27.74M |
| EPS Diluted (Quarterly) | -2.311 |
| Earnings Yield | -195.5% |
| Normalized Earnings Yield | -197.55 |